ClinicalTrials.gg
CompletedNCT00612040Updated Mar 3, 2017Results posted

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

A Phase 2 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 33 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-03.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
21st of 66
178 · median 73
Started
2008
with 3 others
Phase 2
3 of 66
none open now
Registered
13th of 66
by date
Lead sponsor
11 of 66
Novo Nordisk A/S

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is one of 4 that started in 2008, is one of 3 in phase 2, and was the 13th registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 178 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes for at least one year
  • 7-11% (both inclusive)
  • Treated with insulin for at least six months - any regimen

Exclusion criteria

Exclusion Criteria:

  • Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (eg systemic ) 3 months prior to randomisation
  • Subject has a , active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial product
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    SIBA (D)

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    SIBA (E)

    Drug: insulin degludec · Drug: insulin aspart

  • Experimental
    IGlar

    Drug: insulin glargine · Drug: insulin aspart

Interventions

  • Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily

  • Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily

  • Treat-to-target dose titration scheme, injection s.c., once daily

  • Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline in HbA1c after 16 weeks of treatment

    Time frame: Week 0, Week 16

Secondary outcomes

  1. Change in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment

    Time frame: Week 0, Week 16

  2. Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)

    Estimate of the overall mean of SMPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast.

    Time frame: Week 16

  3. Rate of Major and Minor Hypoglycaemic Episodes

    Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.

    Time frame: Week 0 to Week 16 + 5 days follow up

  4. Rate of Nocturnal Major and Minor Hypoglycaemic Episodes

    Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded).

    Time frame: Week 0 to Week 16 + 5 days follow up

  5. Rate of Treatment Emergent Adverse Events (AEs)

    Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.

    Time frame: Week 0 to Week 16 + 5 days follow up

  6. Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)

    Laboratory values at screening (Week -1) and at Week 16

    Time frame: Week -1, Week 16

  7. Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)

    Laboratory values at screening (Week -1) and at Week 16

    Time frame: Week -1, Week 16

  8. Laboratory Safety Parameters (Biochemistry): Serum Creatinine

    Laboratory values at screening (Week -1) and at Week 16

    Time frame: Week -1, Week 16

  9. Vital Signs: Diastolic BP (Blood Pressure)

    Values at baseline (Week 0) and at Week 16

    Time frame: Week 0, Week 16

  10. Vital Signs: Systolic BP (Blood Pressure)

    Values at baseline (Week 0) and at Week 16

    Time frame: Week 0, Week 16

  11. Vital Signs: Pulse

    Values at baseline (Week 0) and at Week 16

    Time frame: Week 0, Week 16

  12. Physical Examination

    Physical examination was performed at screening (week -1), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.

    Time frame: Week -1, Week 8, Week 16

08

Results

Posted Nov 16, 2015

Participant flow

A total of 28 centres participated: Australia (5), Germany (6), Norway (6), Sweden (5) and United States (6).

Participant flow — Overall Study
MilestoneSIBA (D)SIBA (E)IGlar
Started605959
Exposed605959
Completed555252
Not completed577
Withdrew: Adverse event021
Withdrew: Protocol violation121
Withdrew: Lack of efficacy210
Withdrew: Unclassified225

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline in HbA1c after 16 weeks of treatment

Time frame:
Week 0, Week 16
Reported as:
Mean · percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
percentage of glycosylated haemoglobinSIBA (D)SIBA (E)IGlar
Change in Glycosylated Haemoglobin (HbA1c)-0.54 ± 0.78-0.57 ± 0.76-0.62 ± 0.68
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline in FPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment

Time frame:
Week 0, Week 16
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LSIBA (D)SIBA (E)IGlar
Change in Fasting Plasma Glucose (FPG)-2.06 ± 5.17-1.60 ± 4.66-0.54 ± 4.36
SecondaryMean of 9-point Self Measured Plasma Glucose Profile (SMPG)

Estimate of the overall mean of SMPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast.

Time frame:
Week 16
Reported as:
Least squares mean · mmol/L
Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
mmol/LSIBA (D)SIBA (E)IGlar
Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)9.27 ± 0.309.56 ± 0.309.04 ± 0.30
SecondaryRate of Major and Minor Hypoglycaemic Episodes

Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.

Time frame:
Week 0 to Week 16 + 5 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Major and Minor Hypoglycaemic Episodes
Episodes/100 years of patient exposureSIBA (D)SIBA (E)IGlar
Major464136
Minor583853056637
SecondaryRate of Nocturnal Major and Minor Hypoglycaemic Episodes

Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded).

Time frame:
Week 0 to Week 16 + 5 days follow up
Reported as:
Number · Episodes/100 years of patient exposure
Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
Episodes/100 years of patient exposureSIBA (D)SIBA (E)IGlar
Major171218
Minor7695461082
SecondaryRate of Treatment Emergent Adverse Events (AEs)

Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.

Time frame:
Week 0 to Week 16 + 5 days follow up
Reported as:
Number · Events/100 years of patient exposure
Rate of Treatment Emergent Adverse Events (AEs)
Events/100 years of patient exposureSIBA (D)SIBA (E)IGlar
Adverse events (AEs)653874914
Serious AEs6126
Severe AEs6296
Moderate AEs202246397
Mild AEs445599511
Fatal AEs000
SecondaryLaboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)

Laboratory values at screening (Week -1) and at Week 16

Time frame:
Week -1, Week 16
Reported as:
Mean · IU/L
Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)
IU/LSIBA (D)SIBA (E)IGlar
Week -1 , N=60, 59, 5925.5 ± 11.322.7 ± 11.123.1 ± 10.2
Week 16 , N=55, 53, 5425.0 ± 12.021.2 ± 8.023.1 ± 13.0
SecondaryLaboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)

Laboratory values at screening (Week -1) and at Week 16

Time frame:
Week -1, Week 16
Reported as:
Mean · IU/L
Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)
IU/LSIBA (D)SIBA (E)IGlar
Week -1, N=60, 59, 5922.8 ± 7.421.7 ± 7.023.3 ± 11.3
Week 16, N=55, 53, 5423.3 ± 8.821.6 ± 8.523.9 ± 9.4
SecondaryLaboratory Safety Parameters (Biochemistry): Serum Creatinine

Laboratory values at screening (Week -1) and at Week 16

Time frame:
Week -1, Week 16
Reported as:
Mean · umol/L
Laboratory Safety Parameters (Biochemistry): Serum Creatinine
umol/LSIBA (D)SIBA (E)IGlar
Week -1 , N=60, 59, 5977.2 ± 12.676.6 ± 12.877.6 ± 13.3
Week 16 , N=55, 53, 5477.2 ± 14.175.9 ± 13.077.9 ± 14.5
SecondaryVital Signs: Diastolic BP (Blood Pressure)

Values at baseline (Week 0) and at Week 16

Time frame:
Week 0, Week 16
Reported as:
Mean · mmHg
Vital Signs: Diastolic BP (Blood Pressure)
mmHgSIBA (D)SIBA (E)IGlar
Week 0 (Baseline), N=60, 59, 5976 ± 875 ± 1074 ± 9
Week 16, N=60, 57, 5776 ± 1075 ± 1074 ± 7
SecondaryVital Signs: Systolic BP (Blood Pressure)

Values at baseline (Week 0) and at Week 16

Time frame:
Week 0, Week 16
Reported as:
Mean · mmHg
Vital Signs: Systolic BP (Blood Pressure)
mmHgSIBA (D)SIBA (E)IGlar
Week 0 (Baseline), N=60, 59, 59124 ± 15126 ± 16124 ± 16
Week 16, N=60, 57, 57122 ± 14125 ± 14123 ± 15
SecondaryVital Signs: Pulse

Values at baseline (Week 0) and at Week 16

Time frame:
Week 0, Week 16
Reported as:
Mean · beats/minute
Vital Signs: Pulse
beats/minuteSIBA (D)SIBA (E)IGlar
Week 0 (Baseline), N=60, 59, 5974 ± 1072 ± 973 ± 10
Week 16, N=60, 57, 5774 ± 1272 ± 1172 ± 12
SecondaryPhysical Examination

Physical examination was performed at screening (week -1), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.

Time frame:
Week -1, Week 8, Week 16

No measurements were reported for this outcome.

Adverse events

Collected over The adverse events were collected in a time frame of 16 weeks + 5 days follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SIBA (D)—1/60 (1.7%)31/60 (51.7%)
SIBA (E)—2/59 (3.4%)42/59 (71.2%)
IGlar—1/59 (1.7%)31/59 (52.5%)
Most frequent serious events
Most frequent serious events
EventSIBA (D)SIBA (E)IGlar
Abdominal distensionGastrointestinal disorders0/601/590/59
Diabetic ketoacidosisMetabolism and nutrition disorders0/600/591/59
Hypoglycaemic unconsciousnessMetabolism and nutrition disorders0/601/590/59
HypoglycaemiaMetabolism and nutrition disorders1/600/590/59
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSIBA (D)SIBA (E)IGlar
NasopharyngitisInfections and infestations14/6024/5915/59
HeadacheNervous system disorders10/6016/5910/59
Upper respiratory tract infectionInfections and infestations3/602/597/59
InfluenzaInfections and infestations4/606/593/59
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/606/592/59
Back painMusculoskeletal and connective tissue disorders6/603/592/59
NauseaGastrointestinal disorders2/605/592/59
DiarrhoeaGastrointestinal disorders1/602/594/59
SinusitisInfections and infestations1/600/594/59
ConstipationGastrointestinal disorders1/603/591/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)SIBA (D)SIBA (E)IGlarTotal
Mean45.6 ± 12.544.5 ± 12.747.2 ± 13.545.8 ± 12.8
Gender
Gender(Participants)SIBA (D)SIBA (E)IGlarTotal
Female23222772
Male373732106
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)SIBA (D)SIBA (E)IGlarTotal
Mean8.5 ± 1.08.4 ± 0.98.3 ± 0.88.4 ± 0.9
Fasting plasma glucose (FPG)
Fasting plasma glucose (FPG)(mmol/L)SIBA (D)SIBA (E)IGlarTotal
Mean10.3 ± 4.89.9 ± 3.39.5 ± 3.89.9 ± 4.0
09

Study locations

33 sites
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Honolulu, Hawaii 96814, United States
  • Novo Nordisk Investigational Site
    Idaho Falls, Idaho 83404-7596, United States
  • Novo Nordisk Investigational Site
    Des Moines, Iowa 50314, United States
  • Novo Nordisk Investigational Site
    Hyattsville, Maryland 20782, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37404, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Renton, Washington 98057, United States
  • Novo Nordisk Investigational Site
    Wollongong, New South Wales 2500, Australia
  • Novo Nordisk Investigational Site
    Keswick, South Australia 5035, Australia
  • Novo Nordisk Investigational Site
    East Ringwood, Victoria 3135, Australia
  • Novo Nordisk Investigational Site
    Geelong, 3220, Australia
  • Novo Nordisk Investigational Site
    Miranda, 2228, Australia
  • Novo Nordisk Investigational Site
    Aschaffenburg, 63739, Germany
  • Novo Nordisk Investigational Site
    Bad Kreuznach, 55545, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01219, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Hohenmölsen, 06679, Germany
  • Novo Nordisk Investigational Site
    Neuwied, 56564, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Bergen, 5021, Norway
  • Novo Nordisk Investigational Site
    Bergen, NO-5012, Norway
  • Novo Nordisk Investigational Site
    Elverum, 2408, Norway
  • Novo Nordisk Investigational Site
    Kristiansand S, 4604, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0586, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4011, Norway
  • Novo Nordisk Investigational Site
    Alingsås, 441 83, Sweden
  • Novo Nordisk Investigational Site
    Karlstad, 651 85, Sweden
  • Novo Nordisk Investigational Site
    Lund, 221 85, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 112 81, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 182 88, Sweden
  • Novo Nordisk Investigational Site
    Umeå, 901 85, Sweden
10

References and documents

Publications

  • Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26. PubMed 21270174 ↗
  • Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabet Med. 2012 Jun;29(6):716-20. doi: 10.1111/j.1464-5491.2011.03547.x. PubMed 22150786 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 7 years 5 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2008
First posted
Feb 11, 2008
Start
Jan 2008
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results delay requested
Nov 9, 2009
Results first posted
Nov 16, 2015
Last update
Mar 3, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00612040
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 11, 2008
Start date
Jan 2008
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Nov 16, 2015
Last update
Mar 3, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion